Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX – Get Rating) was the recipient of a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 90,800 shares, a growth of 23.9% from the March 31st total of 73,300 shares. Approximately 1.1% of the shares of the company are short sold. Based on an average trading volume of 56,300 shares, the short-interest ratio is presently 1.6 days.
NASDAQ CPIX opened at $2.39 on Tuesday. The company’s 50 day simple moving average is $2.75 and its two-hundred day simple moving average is $3.31. Cumberland Pharmaceuticals has a 1 year low of $2.19 and a 1 year high of $7.51. The company has a current ratio of 2.37, a quick ratio of 1.93 and a debt-to-equity ratio of 0.35.
CPIX has been the subject of a number of research reports. TheStreet downgraded shares of Cumberland Pharmaceuticals from a “c-” rating to a “d+” rating in a research report on Tuesday, February 22nd. StockNews.com began coverage on shares of Cumberland Pharmaceuticals in a research report on Wednesday, April 27th. They set a “hold” rating for the company.
About Cumberland Pharmaceuticals (Get Rating)
Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
- Get a free copy of the StockNews.com research report on Cumberland Pharmaceuticals (CPIX)
- MarketBeat Podcast: Investing In Innovation, Robotics, AI and Healthcare
- It’s Time to Book an Appointment for Teladoc Stock
- Saia Growth Accelerates But It May Not Matter
- GitLab Stock is Trying to Put in a Bottom Here
- onsemi Is A Deep-Value In The Chip Sector
Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.